ONCY

Oncolytics Biotech Inc. [ONCY] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

ONCY Stock Summary

Top 10 Correlated ETFs

ONCY

Top 10 Correlated Stocks

ONCY

In the News

ONCY Financial details

Company Rating
-
Market Cap
85.98M
Income
-27.42M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
29
Optionable
No
Shortable
Yes
Earnings
03 May 2024
P/E
-3.61
Forward P/E
-
PEG
8.44
P/S
-
P/B
3.99
P/C
-
P/FCF
-4.31
Quick Ratio
4.05
Current Ratio
4.53
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.41
EPS next Y
-
EPS next Q
-
EPS this Y
-4.65%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-61.71%
-
-
-
-
SMA20
29.79%
SMA50
64.86%
SMA100
114.04%
Inst Own
-
Inst Trans
-
ROA
-69%
ROE
-124%
ROC
-0.92%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.88-3.39
52W High
-
52W Low
-
RSI
61.3
Rel Volume
2.37
Avg Volume
388.49K
Volume
920.51K
Perf Week
10.34%
Perf Month
25.49%
Perf Quarter
103.14%
Perf Half Y
103.17%
-
-
-
-
Beta
1.46
-
-
Volatility
0.12%, 0.14%
Prev Close
-2.29%
Price
1.28
Change
-3.03%

Something similar

Top by Market Cap
BRYN.DE
AMZ.DE
FB2A.DE
LLY.DE
GOOG
Top Correlated ETFs
ZCH.TO
BBC
IZRL
HFIN.TO
XBAK.L
Top Correlated Stocks
CAPC
KNSA
XTG.TO
FFMGF
5976.T
Similar Market Cap
2728.HK
WNDU.L
ATHA
FBCV
6611.HK

Company Profile

Healthcare Biotechnology
  • Volume Average 388.49K
  • Market Capitalization 85.98M
  • Employee 29
  • CEO Dr. Matthew C. Coffey M.B.A., Ph.D.
  • Headquarters Calgary,AB,CA
  • IPO Date 2001-10-05
  • Website https://www.oncolyticsbiotech.com

Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC. The company was incorporated in 1998 and is headquartered in Calgary, Canada.